This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: September 14, 2009
Last updated: May 8, 2017
Last verified: May 2017

This study is a phase I, open label trial to determine the Maximum Tolerated Dose (MTD), safety, pharmacokinetics, and efficacy of BIBW 2992 (an epidermal growth factor receptor(EGFR)inhibitor) to be used in combination with:

  • radiotherapy alone (in patients with an unmethylated (functioning) MGMT gene regulator) or
  • radiotherapy and Temozolomide (in patients with a methylated (silenced) MGMT gene) to treat newly diagnosed patients with Grade IV Glioblastoma (primary brain cancer).

Condition Intervention Phase
Glioblastoma Drug: Temozolomide Procedure: Radiotherapy Drug: BIBW2992 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • MTD of BIBW 2992 when given concomitantly with Temozolomide (TMZ) and radiotherapy [ Time Frame: 6 weeks ]
  • Maximum Tolerated Dose (MTD) of BIBW 2992 when given concomitantly with radiotherapy [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Safety of BIBW 2992: Incidence and intensity of AEs according to Common Terminology Criteria (CTCAE v.3.0) [ Time Frame: Until disease progression or undue side effect ]
  • Objective tumour response according to the Macdonald criteria [ Time Frame: Until disease progression or undue side effect ]
  • Pharmacokinetics of BIBW 2992 in combination with radiotherapy (RT) with or without concomitant Temozolomide therapy [ Time Frame: day 8, day 15, day 29 ]

Enrollment: 36
Actual Study Start Date: September 17, 2009
Estimated Study Completion Date: September 29, 2017
Estimated Primary Completion Date: September 29, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Regimen U
BIBW2992 + Radiotherapy
Procedure: Radiotherapy
Day 1 to day 42
Drug: BIBW2992
Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
Experimental: Regimen M
BIBW2992 + Temozolomide + Radiotherapy
Drug: Temozolomide
During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
Drug: BIBW2992
Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
Procedure: Radiotherapy
Day 1 to day 42


Ages Eligible for Study:   18 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Histologically-confirmed WHO Grade IV newly diagnosed malignant glioma.
  2. Proven MGMT gene promoter methylation status
  3. Available early postoperative Gd-enhanced MRI (within 72 hours after initial surgery). In case a patient did not perform a Gd-enhanced MRI within 72 hours post surgery, a Gd-MRI is to be performed prior to start of study treatment.
  4. Age more or equal to 18 years and less than 70 years at entry
  5. KPS more or equal to 70%
  6. Patients receiving corticosteroids have to receive a stable or decreasing dose for at least 14 days before start of treatment.
  7. Written informed consent that is consistent with local law and ICH-GCP guidelines.

Exclusion criteria:

  1. Less than two weeks from surgical resection or other major surgical procedure at start of treatment.
  2. Planned surgery for other diseases
  3. Placement of Gliadel® wafer at surgery.
  4. Prior or planned radiotherapy of the cranium including brachytherapy and/or radiosurgery for GBM.
  5. Treatment with other investigational drugs; participation in another clinical study including exposure to the investigational product within the past 4 weeks before start of therapy or concomitantly with this study.
  6. Active infectious disease requiring intravenous therapy.
  7. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
  8. Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea.
  9. Patients with known pre-existing interstitial lung disease
  10. Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the protocol.
  11. Patient is less than 3 years free of another primary malignancy except: if the other primary malignancy is either not currently clinically significant or does not require active intervention (such as a basal cell skin cancer or a cervical carcinoma in situ). Existence of any other malignant disease is not allowed.
  12. Cardiac left ventricular function with resting ejection fraction less than 50%.
  13. Absolute neutrophil count (ANC) less than 1500/mm3.
  14. Platelet count less than 100,000/mm3.
  15. Bilirubin greater than 1.5 x upper limit of institutional norm.
  16. Aspartate amino transferase (AST) greater than 3 x upper limit of institutional norm.
  17. Serum creatinine greater than 1.5 x upper limit of institutional norm.
  18. Patients who are sexually active and unwilling to use a medically acceptable method of contraception.
  19. Pregnancy or breast-feeding.
  20. Patients unable to comply with the protocol.
  21. Known or suspected active drug or alcohol abuse.
  22. Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00977431

United Kingdom
1200.38.4402 Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
1200.38.4405 Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
1200.38.4404 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1200.38.4403 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
1200.38.4401 Boehringer Ingelheim Investigational Site
Sutton, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT00977431     History of Changes
Other Study ID Numbers: 1200.38
2008-007284-17 ( EudraCT Number: EudraCT )
Study First Received: September 14, 2009
Last Updated: May 8, 2017

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on June 23, 2017